Cell and gene therapy solutions
-
23
Active FDA approved therapies
-
$25B
Anticipated category spend by 2026
-
284
therapies in the pipeline in Phase 1-3 of development
We anticipate 35 novel therapies in the market by 2026. The treatment of rare genetic disorders continues to grow with a target on disorders such as sickle cell, hemophilia, spinal muscular atrophy and several oncology disease states.
Challenging factors
Navigating the complex landscape
- Access: Qualified treatment centers and limited hospital capacity challenge implementation in health systems.
- Cost: The high cost of gene therapy necessitates discussion on long-term affordability and patient assistance programs.
- Reimbursement: Health systems must work closely with their finance and payer management teams to create single-case agreements.
- Operations: Lacking clear guidelines, institutions must individually assess and develop policies for the safe handling of therapies.
$0.00 million
Gene therapies cost as much as $4.25M
+Contact usClick here
Connect with our experts
For more information about our cell and gene therapy solutions, contact us.
Speak with our team of experts to learn more
Let’s discuss your challenges
Tell us a little more about how we can help you. Here's what we're going to do with the details you share:
- Identify the person or resource best suited to help you with your challenge.
- Contact you to address it directly.